SETD2 and renal cell carcinoma: Subsequently genomic studies have shown intrinsic differences in RCC between AA and White patients, focusing specifically on the nine most common mutations: VHL, protein polybromo‐1 human (PBRM1), SET domain containing 2 (SETD2), lysine‐specific demethylase 5C (KDM5C), phosphatase and tensin homolog (PTEN), BRCA1‐associated protein 1 (BAP1), mTOR, tumor protein p53 (TP53) and phosphoinositide 3‐kinase (PI3KC).